8
eFlow
®
rapid
Intended purpose
The eFlow
®
rapid
nebuliser system is
intended to administer nebuliser solutions
or suspensions as an aerosol for
inhalation.
Indication
The eFlow
®
rapid
nebuliser system is
indicated to administer nebuliser solutions
or suspensions approved for the treatment
of diseases of the lower airways.
Intended use
The nebuliser system must only be used
in accordance with its intended purpose.
The frequency of inhalation sessions may
vary depending on the nebuliser solutions
or suspensions and the clinical picture.
Take note of any limitations in the pack-
age leaflet accompanying the respective
nebuliser solutions or suspensions.
For reasons of hygiene and to avoid
cross-infections, the eFlow
®
rapid
nebu-
liser handset and the connection cord
must only be used by one patient. For
patients at greater risk from infection, e.g.,
with cystic fibrosis (CF) or a weakened
immune system, or for those infected with
MRSA it is recommended that the
eBase
®
Controller and the power adapter
are also used by only one patient.
Only original PARI accessories must be
used to operate the system (see "SPARE
PARTS AND ACCESSORIES", page 26).
PARI Pharma GmbH is not responsible
for damage if the system is used
improperly or contrary to the instructions.
Contraindications
For the eFlow
®
rapid
nebuliser system no
contraindication is known to
PARI Pharma GmbH. Take note of con-
traindications of the medicine in the
accompanying package leaflet.
Info:
The
eBase
®
Controller
can also be
used for a medication-specific nebu-
liser handset (
Tolero
®
,
Zirela
®
and
Altera
®
). Follow the instructions for
use of the nebuliser handset as well.
CAUTION:
Medications that are approved for inhala-
tion with a medication-specific nebuliser
handset must not be used with an
eFlow
®
rapid
nebuliser handset (risk of
incorrect dosage).
CAUTION:
Never attempt to inhale essential oils, as
this can cause irritation of the airways
(intense coughing).
CAUTION:
Using accessories and spare parts other
than those supplied by the manufacturer
may cause increased electromagnetic
emissions or reduced electromagnetic
immunity, leading to a malfunction.
Summary of Contents for eFlow rapid
Page 6: ...2 eFlow rapid 2021 04...
Page 36: ...32 eFlow rapid 2021 04...
Page 66: ...62 eFlow rapid 2021 04...
Page 69: ...eFlow rapid 2021 04 65 el 1...
Page 70: ...66 eFlow rapid 2021 04...
Page 75: ...eFlow rapid 2021 04 71 el 9a Controller Controller 5a 9a 5a...
Page 76: ...72 eFlow rapid 2021 04 3 6 7 60 3 6 7...
Page 77: ...eFlow rapid 2021 04 73 el 8 8 Controller 8 8 6 ml...
Page 78: ...74 eFlow rapid 2021 04...
Page 80: ...76 eFlow rapid 2021 04 Controller Controller 83 eFlow rapid 1 ml 1 ml...
Page 81: ...eFlow rapid 2021 04 77 el 78...
Page 82: ...78 eFlow rapid 2021 04 5 3 5 37 C 5 5 3 easycare 2 easycare...
Page 83: ...eFlow rapid 2021 04 79 el 6...
Page 84: ...80 eFlow rapid 2021 04 5 81...
Page 87: ...eFlow rapid 2021 04 83 el 6 Controller ON OFF 20 ON OFF...
Page 89: ...eFlow rapid 2021 04 85 el easycare easycare easycare easycare...
Page 90: ...86 eFlow rapid 2021 04...
Page 94: ...90 eFlow rapid 2021 04 EN 60601 1 eFlow rapid II BF IEC 60529 IP IP 21...
Page 96: ...92 eFlow rapid 2021 04 10 BF CE 93 42 13 2005...
Page 97: ...eFlow rapid 2021 04 93 el 11 PARI PARI PARI PARI...
Page 140: ...136 eFlow rapid 2021 04 Gakktu r skugga um a allar tengingar s u ttar og a lyfh lfi s l st...
Page 190: ...186 eFlow rapid 2021 04...
Page 250: ...246 eFlow rapid 2021 04...
Page 281: ......
